XtalPi Wechat Account
08.09.2025
On September 8, 2025, XtalPi announced that PEP08, a next-generation PRMT5 inhibitor discovered in collaboration with PharmaEngine, Inc., has reached a significant clinical development milestone. PEP08 recently received approval for Phase I clinical trials in solid tumors from Australia's Human Research Ethics Committee (HREC), the Therapeutic Goods Administration (TGA), as well as Taiwan's "Food and Drug Administration" (TFDA). XtalPi confirmed receiving milestone payments for this project.
Disclaimer
Investment Involves risk. Past performance does not represent future performance. Investor should read the product’s Prospectus for details and risk factors before making investment decision. The contents of this website is prepared and maintained by Mirae Asset Capital (China) Limited. This material has not been reviewed by the Securities and Futures Commission. Certain information contained in this website is compiled from third party sources. Whilst we have, to the best of its endeavor, ensured that such, information is accurate, complete and up-to-date, and has taken care in accurately reproducing the information. We accepts no liability for, any loss or damage of any kind resulting out of the unauthorized use of this website.
Sep 28, 2025
